The President's Vision

Welcome to the Metastasis Research Society!

The metastatic spread of cancer to vital organs is the single most common cause of cancer-related mortality.  This is a highly complicated problem that requires concerted efforts of researchers, clinicians, drug developers, patients and their supporters. The mission of the Metastasis Research Society (MRS) is to foster the collaboration between all stakeholders of the metastasis research and advocacy community, promote the dissemination and exchange of information about latest research and treatment advances, support the career development of young scientists in the field, and advocate for funding support and favorable policy changes for metastasis research, drug development and patient care. 

To achieve these goals, the MRS organizes our international biennial congresses and special conferences in different locations around the world, often times in partnership with our sister organizations globally, including the American Association for Cancer Research (AACR), the European Association for Cancer Research (EACR), the Japanese Association for Metastasis Research (JAMR), the Chinese Society of Tumor Metastasis (CSTM) and the Australian Metastasis Research Society (OzMRS). Our next special conference on metastasis models, co-organized with the EACR, will be held in Berlin on November 27-29, 2017. I would also like to send an early invitation to welcome you to our next International Biennial Congress, to be held in the beautiful and historic campus of Princeton University on August 1-5, 2018.  This conference will feature a one-day young investigator satellite meeting on August 1st, organized by the Early Career Embassadors of the MRS (ECAM) section of the society, and a session dedicated to patient advocacy and policy. These special sessions reflect the Society’s dedication to facilitate the career advancement of young scientist and integrate patient input in focusing our research and development efforts on the most urgent problems faced by metastatic cancer patients. Through our long-term partnership with patient advocacy organizations such as METAvivor, the MRS strives to build a platform to facilitate the cooperation and exchange of information between metastasis researchers and clinicians, and patients/advocates.  By joining the new “supporting member” category of MRS membership, patients, advocates, and families can lend their voice to the development and execution of patient-centered cancer metastasis research projects and grants, while gaining a “seat at the bench” to learn about the latest advance in metastasis research and drug development in easily accessible terms.

A sea of change is happening in metastasis research and treatment.  Years of research have led to a deep understanding about the pathogenesis of metastatic diseases, although many mysteries remain to be solved.  Many late stage cancers that have been previously considered incurable or even untreatable are now having dramatic response to newly developed therapies.  This is an exciting time for metastasis research, and I hope you join the MRS and support our effort to understand and defeat metastatic cancer.


Yibin Kang, Ph.D.

Warner-Lambert/Parke-Davis Professor of Molecular Biology
Department of Molecular Biology
Princeton University